[{"Assets_0_Q2_USD":421364000.0,"CommonStockSharesOutstanding_0_Q2_shares":55104000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-11712000.0,"NetIncomeLoss_1_Q2_USD":-40818000.0,"NetIncomeLoss_2_Q2_USD":-105905000.0,"StockholdersEquity_0_Q2_USD":34387000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":23476000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":31795000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180802"}]